Despite high p16INK4a or p53 mutation rates, multiple evidences show that cancer cells can retain the capacity to develop some senescence-associated (SA) phenotypes in response to treatment (Therapy-induced senescence or TIS) [16,20,27,28,29,30,31]. This evidence concerns the gene CDKN2A and cancer.